FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2029

Conditions
Metastatic Breast CancerResponse Monitoring
Interventions
DIAGNOSTIC_TEST

FDG-PET/CT

FDG-PET/CT is used regulary for a continuous, long term monitoring

DIAGNOSTIC_TEST

CE-CT

CE-CT is used regulary for a continuous, long-term monitoring

Trial Locations (11)

2100

NOT_YET_RECRUITING

Rigshospitalet, Copenhagen

2730

NOT_YET_RECRUITING

Herlev and Gentofte Hospital, Herlev

5000

RECRUITING

Odense University Hospital, Odense

6400

NOT_YET_RECRUITING

Hospital of Southern Jutland, Sønderborg

6700

NOT_YET_RECRUITING

Esbjerg and Grindsted Hospital, Esbjerg

7100

NOT_YET_RECRUITING

Lille Baelt Hospital, Vejle

8200

NOT_YET_RECRUITING

Aarhus University Hospital, Aarhus

9000

NOT_YET_RECRUITING

Aalborg University Hospital, Aalborg

20089

NOT_YET_RECRUITING

Humanitas Research Hospital, Milan

40138

NOT_YET_RECRUITING

Irccs Azienda Ospedaliero - Universitario Di Bologna, Bologna

81675

NOT_YET_RECRUITING

Klinikum Der Technischen Universität München, München

All Listed Sponsors
lead

Odense University Hospital

OTHER